A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Sintilimab Plus Ipilimumab N01 and Chemotherapy in Patients With Resectable cN1/N2 Driver Gene-Negative Non-Small Cell Lung Cancer (ChiCTR) - Oct 16, 2026 - P2 | N=66 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New P2 trial • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • HER-2 • ROS1
|